Chief Science Officer

Dave has fifty years of experience in development, formulation, manufacturing, and quality control of products in the pharmaceutical and nutraceutical industry. His emphasis has been on unique delivery systems. This includes quick-dissolve lozenges, chewable tablets, timed-release capsules, gummies, instantized powders, ingestible liquid preparations, topical liquid applications, ocular solutions, muco-adhesive gels, and oro-buccal sprays.

 His education was in biology, synthetic organic chemistry, and bio-organic chemistry. Undergraduate work was at Loyola University of Los Angeles, graduate work at California State University, Los Angeles and University of California, Irvine. He also has a degree in law from Western University College of Law.

 In 1980, he co-founded and co-owned Bioglan Laboratories, Inc., which later became Micelle Laboratories, Inc. This was an FDA drug licensed product development and manufacturing company. It formulated and manufactured specialty products for the U.S., Asian and European markets. During that time, Dave pioneered the patented micellized delivery system. He sold his interest in the company in 2001.

 From 2001 until 2013, Dr. Rutolo continued to consult on product development projects.

In 2013, he became the Director of Science for Medlab Clinical US, Inc. He was instrumental in the development of the NanoCelle delivery system technology, which was eventually patented in the U.S. and over thirty other countries. A number of formulations have been created using this technology, including NanaBis, as a non-addictive pain product. There have been clinical trials, with positive results, described in multiple scientific publications and presentations. Current research efforts are ongoing with a wide range of potential therapeutic products using the NanoCelle technology.